Physician profile
Gregory S Lenchner
NPI 1154302040
$9,760.06
in general payments reported to CMS, 2019-2025
36 companies · $592 in 2025
The $592 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,033 · 2020: $1,406 · 2021: $1,575 · 2022: $1,583 · 2023: $1,429 · 2024: $1,142 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,895 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,894.98 |
| Education | $267.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,342.58 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals Lp | $1,758.88 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Insmed, INC. | $844.04 | 2019-2024 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $824.41 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Actelion Pharmaceuticals US, INC. | $770.34 | 2019-2023 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $745.48 | 2019-2025 | Dupixent |
| Advanced Respiratory, INC | $284.59 | 2019-2021 | |
| Genzyme Corporation | $276.18 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $183.22 | 2020-2025 | Acthar |
| Genentech USA, INC. | $123.41 | 2019-2022 | |
| Daiichi Sankyo INC. | $123.36 | 2019 | |
| Philips North America LLC | $120.23 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $113.83 | 2020-2022 | |
| Vifor Pharma, INC. | $113.49 | 2019 | |
| Harmony Biosciences LLC | $111.47 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.42 | 2019 | |
| Sunovion Pharmaceuticals INC. | $94.45 | 2019 | |
| Allergan, INC. | $93.62 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $85.96 | 2021 | |
| Sanofi-Aventis U.S. LLC | $76.99 | 2023 | |
| Verona Pharma, INC. | $75.00 | 2025 | Ohtuvayre |
| Electromed, INC. | $72.80 | 2021-2024 | Smartvest |
| Grifols USA, LLC | $52.49 | 2019-2023 | Prolastin-C Liquid |
| Paratek Pharmaceuticals, INC. | $44.38 | 2023-2024 | Nuzyra |
| Circassia INC. | $43.03 | 2019 | |
| Jazz Pharmaceuticals INC. | $38.37 | 2019-2021 | |
| Vapotherm INC | $36.78 | 2021 | |
| Janssen Pharmaceuticals, INC | $30.15 | 2023 | Xarelto |
| Mylan Specialty L.P. | $28.59 | 2023 | Yupelri |
| Medtronic, INC. | $24.37 | 2025 | Illumisite |
| Lilly USA, LLC | $24.16 | 2025 | Zepbound |
| Mallinckrodt Enterprises LLC | $22.30 | 2019 | |
| Ani Pharmaceuticals, INC. | $20.65 | 2024 | Purified Cortrophin Gel |
| Amgen INC. | $19.54 | 2022 | |
| Baxter Healthcare | $17.89 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Lenchner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.